Guardant Health, Inc. reported total revenue of $201.8 million for the fourth quarter of 2024, a 30% increase year-over-year. For the full year 2024, total revenue reached $739.0 million, representing a 31% increase from 2023.
The company reported a net loss of $110.8 million, or $0.90 per share, for Q4 2024, and a full-year net loss of $437.7 million, or $3.58 per share. Non-GAAP net loss for Q4 was $0.50 per share, and for the full year was $1.93 per share.
For 2025, Guardant Health provided revenue guidance in the range of $850 million to $860 million, representing 15% to 16% growth over 2024. The company expects oncology revenue to grow approximately 18% to 19%, biopharma and data revenue to grow mid-teens, and Shield revenue to be between $40 million and $45 million. Non-GAAP gross margin is projected to be 62% to 63%, with free cash flow burn expected to improve to $225 million to $235 million, and the core business (excluding screening) on track to reach free cash flow breakeven in Q4 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.